Trial Profile
Real-world evidence comparing outcomes in routine clinical practice among patients initiating Canagliflozin versus Sitagliptinin.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Oct 2017
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary) ; Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 04 Oct 2017 New trial record
- 12 Sep 2017 Results published in the Clinical Therapeutics